Video Series

Collaborative care from medical and surgical oncologists as well as supportive care teams provides an optimal treatment environment for patients facing mCRC diagnosis.

Experts review their considerations when adding immunotherapy to both surgical patients and radiation patients with NSCLC.

Experts discuss the current standard treatment options for patients diagnosed with early-stage NSCLC [non-small cell lung cancer].

A conversation on patient tolerance of CTLA-4 immunotherapies, alongside an exploration of treatment-related adverse reactions is discussed by a panel of experts.

John Anderson, MD, discusses the management of quality care for patients with CKD.

Ken Cohen, MD, illustrates payer programs designed to support patient care in CKD treatment.

Closing thoughts from all panel members.

A conversation on the pros and cons of telehealth in acne treatment.

Dr Gerds explores the pros and cons of the present treatment approach for PV.

Dr Gordon provides strategies for navigating treatment-associated toxicities in DLBCL management as directed by NCCN Guidelines.

Dr Gerds provides insight regarding the evaluation of dosing and effectiveness in PV treatment.

A medical expert examines first6, second-, and third-line systemic therapies for DLBCL in accordance with NCCN Guidelines.

Experts explore the importance of early detection of metastatic colorectal cancer.

Specialists examine techniques for assessing pathological complete responses and various methods for response measurement in patients with NSCLC.

Experts explore strategies to increase the number of patients benefiting from multidisciplinary team (MDT) collaboration and the factors MDTs consider when deciding between surgical resection and nonsurgical options for early-stage NSCLC.

Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis.

Specialists evaluate their clinical strategies for managing second-line driver-negative and initial PD-L1 negative patients.

Medical experts discuss considerations for ESRD during CKD treatment as well as updated guidelines for treatment of chronic kidney disease.

Jennifer Green, MD, provides considerations for the use of SGLT2 inhibitors in treatment of CKD.

An overview on the current role of caregivers on patient adherence.

An explanation on the importance of cooperation on the side of providers, payers, and pharmacists in treatment of patients.

Medical experts discuss the financial impact of early detection in colorectal cancer.

Ryan Haumschild, PharmD, MS, MBA, drives a conversation regarding the epidemiology of metastatic colorectal cancer (mCRC) in the US.

Key recommendations and recent updates in the latest version of NCCN guidelines for DLBCL are outlined by Dr Gordon.

Leo Gordon, MD, provides an overview of current treatment strategies currently driven by NCCN guidelines.

Dr Gerds navigates frontline treatments for patients diagnosed with PV.

Dr Gerds reviews the process for updating NCCN guidelines surrounding PV treatment.

Experts examine decision-makers in treatment selection and navigate challenges in organizing multidisciplinary team meetings, from institutional to wider practice perspectives.